FORMIGA, Tássia Camila Mathias.
Resumen:
Chronic diseases affect people of all ages, with heart diseases as the most
important, due to their important relevance in terms of morbidity and mortality.
Cardiovascular diseases are among the main diseases that affect people in the
world, in different age groups. Among these, Dilated Cardiomyopathy stands out,
which as a consequence can cause Heart Failure. Such diseases are caused by
hereditary or genetic factors and cause the simultaneous use of drugs, that is,
polypharmacy; in these cases, the role of the pharmacist is highlighted both in
the dispensation and in the orientation for correct adherence to the treatment,
thus reducing the problems related to the medication. The aim of this study was
to investigate, through a literature review, the consequences of polypharmacy in
cardiac patients, with dilated cardiomyopathy and heart failure and to highlight
the role of the pharmacist in this context. The study consisted of an integrative
review, carried out in electronic databases, using the following terms and their
combinations: dilated cardiomyopathy, heart failure, polypharmacy and NYHA
classification. Studies of the last 06 years were sought in Portuguese, English
and Spanish. 87 studies were found, using 64 of these, to compose this review.
All classes of drugs researched are effective in the treatment of dilated
cardiomyopathy and heart failure. PF has been associated with cardiovascular
disease due to the need for combined therapies and the classification of HF,
such as NYHA IV, which does not allow physical activity, which could be used as
a non-pharmacological treatment, thus increasing the amount of drugs for
treatment of these patients. Thus, it is associated with an increased risk of
negative health outcomes, such as higher health costs, adverse drug reactions
(ADRs), drug interactions (IMs), less adherence to treatment, and even
psychological disorders.
